It was interesting that nothing was mentioned about nnz2591 for Rett syndrome in the presentation.
I am confident the company is underplaying their hand for obvious reasons
Ann: DAYBUE (trofinetide) 2024 net sales US$348 million, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.36 |
Change
0.510(3.97%) |
Mkt cap ! $1.652B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.093M | 312.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 296 | $13.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.37 | 1062 | 3 |
View Market Depth
| Last trade - 11.53am 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |